AMAG Austria Metall Valuation
Is AM8 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of AM8 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AM8 (€22.7) is trading below our estimate of fair value (€35.75)
Significantly Below Fair Value: AM8 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AM8?
Key metric: As AM8 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is AM8's PE Ratio? | |
|---|---|
| PE Ratio | 15.9x |
| Earnings | €50.99m |
| Market Cap | €811.07m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.9x |
| Enterprise Value/EBITDA | 7.7x |
| PEG Ratio | 1x |
Price to Earnings Ratio vs Peers
How does AM8's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 12.6x | ||
STO3 Sto SE KGaA | 11x | 3.5% | €723.6m |
ACT AlzChem Group | 12.1x | 12.6% | €606.5m |
EIS Eisen- und Hüttenwerke | 18.5x | n/a | €202.4m |
NDA Aurubis | 9x | -6.2% | €3.4b |
AM8 AMAG Austria Metall | 15.9x | 16.4% | €811.1m |
Price-To-Earnings vs Peers: AM8 is expensive based on its Price-To-Earnings Ratio (15.9x) compared to the peer average (12.6x).
Price to Earnings Ratio vs Industry
How does AM8's PE Ratio compare vs other companies in the European Metals and Mining Industry?
| 15 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 15 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: AM8 is expensive based on its Price-To-Earnings Ratio (15.9x) compared to the European Metals and Mining industry average (12.1x).
Price to Earnings Ratio vs Fair Ratio
What is AM8's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 15.9x |
| Fair PE Ratio | 13.2x |
Price-To-Earnings vs Fair Ratio: AM8 is expensive based on its Price-To-Earnings Ratio (15.9x) compared to the estimated Fair Price-To-Earnings Ratio (13.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €22.70 | €32.25 +42.1% | 5.4% | €34.00 | €30.50 | n/a | 2 |
| Nov ’25 | €24.60 | €32.25 +31.1% | 5.4% | €34.00 | €30.50 | n/a | 2 |
| Oct ’25 | €23.50 | €32.25 +37.2% | 5.4% | €34.00 | €30.50 | n/a | 2 |
| Sep ’25 | €23.80 | €32.25 +35.5% | 5.4% | €34.00 | €30.50 | n/a | 2 |
| Aug ’25 | €24.60 | €32.25 +31.1% | 5.4% | €34.00 | €30.50 | n/a | 2 |
| Jul ’25 | €25.60 | €32.25 +26.0% | 5.4% | €34.00 | €30.50 | n/a | 2 |
| Jun ’25 | €26.60 | €32.25 +21.2% | 5.4% | €34.00 | €30.50 | n/a | 2 |
| May ’25 | €26.60 | €33.40 +25.6% | 1.8% | €34.00 | €32.80 | n/a | 2 |
| Apr ’25 | €26.90 | €33.40 +24.2% | 1.8% | €34.00 | €32.80 | n/a | 2 |
| Mar ’25 | €27.60 | €33.40 +21.0% | 1.8% | €34.00 | €32.80 | n/a | 2 |
| Feb ’25 | €28.00 | €33.40 +19.3% | 1.8% | €34.00 | €32.80 | n/a | 2 |
| Jan ’25 | €26.20 | €36.40 +38.9% | 9.9% | €40.00 | €32.80 | n/a | 2 |
| Dec ’24 | €26.60 | €36.40 +36.8% | 9.9% | €40.00 | €32.80 | n/a | 2 |
| Nov ’24 | €28.40 | €36.40 +28.2% | 9.9% | €40.00 | €32.80 | €24.60 | 2 |
| Oct ’24 | €28.00 | €36.60 +30.7% | 8.1% | €40.00 | €32.80 | €23.50 | 3 |
| Sep ’24 | €30.30 | €36.60 +20.8% | 8.1% | €40.00 | €32.80 | €23.80 | 3 |
| Aug ’24 | €30.80 | €36.60 +18.8% | 8.1% | €40.00 | €32.80 | €24.60 | 3 |
| Jul ’24 | €32.10 | €35.33 +10.1% | 13.1% | €40.00 | €29.00 | €25.60 | 3 |
| Jun ’24 | €32.90 | €35.33 +7.4% | 13.1% | €40.00 | €29.00 | €26.60 | 3 |
| May ’24 | €33.80 | €35.33 +4.5% | 13.1% | €40.00 | €29.00 | €26.60 | 3 |
| Apr ’24 | €35.80 | €35.33 -1.3% | 13.1% | €40.00 | €29.00 | €26.90 | 3 |
| Mar ’24 | €36.20 | €35.00 -3.3% | 13.0% | €40.00 | €29.00 | €27.60 | 3 |
| Feb ’24 | €34.20 | €35.00 +2.3% | 13.0% | €40.00 | €29.00 | €28.00 | 3 |
| Jan ’24 | €33.70 | €35.00 +3.9% | 13.0% | €40.00 | €29.00 | €26.20 | 3 |
| Dec ’23 | €33.60 | €35.00 +4.2% | 13.0% | €40.00 | €29.00 | €26.60 | 3 |
| Nov ’23 | €29.70 | €35.00 +17.8% | 13.0% | €40.00 | €29.00 | €28.40 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Stanmore Resources
AU$2.8b
Engages in the exploration, development, production, and sale of metallurgical coal in Australia.
S0D
AU$1.91
7D
4.9%
1Y
-15.5%
Tokuyama
JP¥196.7b
Produces and sells various chemical products in Japan.
TBT
JP¥16.60
7D
5.7%
1Y
14.5%
Arkema
€5.7b
Manufactures and sells specialty chemicals and advanced materials worldwide.
V1S
€74.55
7D
-4.4%
1Y
-19.9%